Futibatinib & DurvalumabFutibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy

Sponsor:

Yuanquan Yang

Code:

NCT06263153

Conditions

Bladder Urothelial Carcinoma

Muscle Invasive Bladder Carcinoma

Stage II Bladder Cancer AJCC v8

Stage IIIA Bladder Cancer AJCC v8

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Biospecimen Collection

Computed Tomography

Durvalumab

Futibatinib

Magnetic Resonance Imaging

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-02. This information was provided to ClinicalTrials.gov by Yuanquan Yang on 2025-12-17.